Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study

BACKGROUND: The aim of the study was to determine the maximal tolerated dose (MTD) of gemcitabine every two weeks concurrent to radiotherapy, administered during an aggressive program of sequential and simultaneous radiochemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagel, Bernd, Piroth, Marc, Pinkawa, Michael, Reinartz, Patrick, Krohn, Thomas, Kaiser, Hans J, Stanzel, Sven, Breuer, Christian, Asadpour, Branka, Schmachtenberg, Axel, Eble, Michael J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931600/
https://www.ncbi.nlm.nih.gov/pubmed/17598906
http://dx.doi.org/10.1186/1471-2407-7-112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931600/
https://www.ncbi.nlm.nih.gov/pubmed/17598906
http://dx.doi.org/10.1186/1471-2407-7-112

Ejemplares similares